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 Abstract 
 Background: In left ventricular assist device (LVAD) recip-
ients, plasma levels of interleukin (IL)-6 are associated 
with Interagency Registry for Mechanically Assisted Cir-
culatory Support (INTERMACS) profiles, reflecting post-
operative risk. However, it is not clear how the cardiac 
level of IL-6, detectable on the tissue samples at the time 
of implantation, can contribute to predict the post-opera-
tive outcome. 
 Methods: In 40 LVAD recipients, blood and myocar-
dial samples from LV-apex were collected at the time of 
implantation to assess plasma and cardiac IL-6 levels. 
Serum C-reactive protein (CRP) levels were considered 
as inflammatory variable routinely used in LVAD-based 
therapy. 
 Results: Cardiac IL-6 levels did not correlate with either 
plasma IL-6 levels (R = 0.296, p = 0.063) and tissue IL-6 
mRNA expression (R = – 0.013, p = 0.954). Contrary to what 
happened for the plasma IL-6 and CRP, no differences 
were observed in cardiac IL-6 levels with respect to INTER-
MACS profiles (p = 0.090). Furthermore, cardiac IL-6 con-
centrations, unlike IL-6 and CRP circulating levels, were 
not correlated with the length of intensive care unit stay 
and hospitalization. 
 Conclusions: Cardiac IL-6 levels do not contribute to 
improve risk profile of LVAD recipients in relation to clini-
cal inpatient post-implantation. Instead, plasma IL-6 and 
serum CRP concentrations are more effective in predict-
ing the severity of the clinical course in the early phase of 
LVAD therapy. 
 Keywords:  C-reactive protein;  interleukin-6;  mechanical 
circulatory support;  myocardium. 
 Introduction 
 In the last decades, the left ventricular assist device 
(LVAD) implantation has become an adequate therapy for 
end-stage heart failure (ESHF) patients waiting for heart 
transplantation (HT). However, favorable outcomes still 
depend on proper patient selection, strategic timing of 
implantation, peri-operative risk and long-term clinical 
management  [1] . 
 Indeed, the patients characterized by the worst hemo-
dynamic condition, as defined by Interagency Registry for 
Mechanically Assisted Circulatory Support (INTERMACS) 
profiles, are associated with poorer outcome  [2] . 
 As a result of the interaction within blood cellular com-
ponent and artificial surfaces of mechanical circulatory 
support (MCS), a significant change in systemic immuno-
logic and thrombostatic functions occurs when the device 
was implanted. LVAD implantation results in an altered 
state of monocyte and T-cell activation and an increased 
production of proinflammatory cytokines  [3] . These alter-
ations may cause the early onset of LVAD complications, 
such as multi-organ failure (MOF)  [4, 5] , highlighting the 
importance of inflammatory status monitoring during the 
clinical management of patients needing MCS. 
 The C-reactive protein (CRP) is the main inflamma-
tory variable used routinely in the setting of LVAD patients, 
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although it represents a non-specific inflammatory marker 
 [6] . CRP levels were found comparable between LVAD 
patients either with different outcome and clinical course  [7] . 
 Interleukin (IL)-6 is a cytokine involved in the pro-
gression of HF that plays an important role in prognosis 
of LVAD patients; in fact, signals depending on IL-6 levels 
may trigger monocyte activation, a crucial mechanism 
in the development of MOF  [5, 6] . Circulating IL-6 levels, 
measured at pre- and post-LVAD implantation, increased 
in patients with the worst INTERMACS profiles with 
respect to patients hemodynamically more stable  [8] , sug-
gesting that plasma IL-6 levels correlated with a poor prog-
nosis and the post-operative outcome in LVAD candidates. 
 However, it is still unclear how myocardial pro-
inflammatory cytokine might influence the early outcome 
of LVAD patients, compared to the systemic inflammation. 
Previous studies showed an increased expression of myo-
cardial IL-6 and tumor necrosis factor- α (TNF- α ) in dete-
riorating patients who required LVAD insertion  [9, 10] . The 
aim of our study was to determine whether pre-implant 
cardiac IL-6 levels, as plasma IL-6 concentrations, may 
improve the prediction of post-implant outcome. More-
over, we would verify if IL-6 concentrations, both at 
cardiac or plasma levels, may be more effective in risk 
stratification compared to serum CRP levels. 
 Materials and methods 
 Patients and study design 
 Forty consecutive ESHF patients who underwent LVAD implantation as 
a bridge to HT were enrolled  [11] between May 2006 and December 2012. 
Thirty-nine patients were supported by axial continuous fl ow devices 
(such as Heart Mate II Thoratec, Pleasanton, CA, USA; Incor, Berlin 
Heart AG, Berlin, Germany; De Bakey, MicroMed Technology, Inc., Hou-
ston, TX, USA), and one patient was supported by centrifugal continu-
ous fl ow device (HeartWare International Inc., Framingham, MA, USA). 
The INTERMACS classifi cation was applied by agreement between car-
diologists and cardiac surgeons: nine patients were classifi ed as INTER-
MACS profi le 1, eight as profi le 2, 22 as profi le 3, and one as profi le 4. 
 MOF was monitored pre-operatively and up to 2 weeks aft er 
intervention, calculating the total Sequential Organ Failure Assess-
ment (tSOFA) score  [12] . Length of intensive care unit (ICU) stay and 
hospitalization were considered as end-points, while ICU and 1-year 
survivals were taken into account as main adverse outcomes. 
 Blood samples were collected at pre-implant for determination 
of plasma IL-6 and serum CRP levels. Myocardial specimens were 
obtained from LV apex biopsy, produced by infl ow cannula position-
ing during standard surgical procedure of LVAD implantation. 
 The study protocol conformed to the principles outlined in the 
Declaration of Helsinki and was approved by the Local Ethics Com-
mittee of the Niguarda C à Granda Hospital. All subjects gave written 
informed consent to participate in the study. 
 Cardiac and circulating determinations 
 Deep frozen myocardial specimens, placed in a pre-cooled Tefl on 
shaking fl ask, were ground using a Mikro-Dismembrator II (B. Braun 
Biotech International GmbH, Melsungen, Germany). Frozen tissue 
powder was treated with Tris-based lysis solution and IL-6 levels 
were assessed in the supernatant. 
 Cardiac and plasma IL-6 levels were measured using enzyme-
linked immunosorbent assay (R&D Systems, Minneapolis, MN, USA). 
Cardiac IL-6 levels were normalized by total protein value. 
 CRP levels were measured by high-sensitive immuno-nephelo-
metric method (Roche Diagnostic GmbH, Mannheim, Germany). 
 Cardiac IL-6 mRNA expression 
 Total RNA was extracted from myocardial specimens and RNA con-
centration and purity were evaluated  [13] . Starting from total RNA, 
fi rst-strand cDNA was synthesized by iScript cDNA Synthesis kit (Bio-
Rad, Hercules, CA, USA). Primer Express Version 2.0 (Applied Bio-
systems Inc., Drive Foster City, CA, USA) was used for designing IL-6 
primers. Real-time PCR was performed in duplicate using the Bio-Rad 
C1000TM thermal cycler (CFX-96 real-time PCR detection systems; 
Bio-Rad, Hercules, CA, USA). IL-6 relative quantifi cation was obtained 
by  Δ Δ Ct method using previously selected reference genes  [13] . 
 Histology and immunohistochemistry 
 In nine patients, the proximal portion of surgically excised LV-apex 
was placed in 5% formalin solution (pH 7.0) for traditional histo-
logical staining (hematoxylin & eosin). Masson ’ s trichrome was 
performed for collagen staining and total and interstitial fi brosis 
according to Drakos SG  [14] . Immunohistochemistry of IL-6 (mouse, 
multifunctional protein Santa Cruz Biotechnology, diluted 1:100), 
macrophage marker CD68 (macrophage marker Ab-4 mouse, Thermo 
Scientifi c, Inc., Waltham, MA, USA, diluted 1:50), and macrophage 
migration inhibitory factor (MIF, rabbit polyclonal, Santa Cruz Bio-
technology, Inc. Dallas, TX-USA, diluted 1:250) was also made. 
 Histology and immunohistochemistry staining were performed on 
10 adjacent sections (5  μ m thick) of paraffi  n-embedded surgical speci-
mens mounted on positively charged glass slides. Treatment for primary 
and secondary antibody binding was followed according to standard-
ized protocol for immunohistochemistry of paraffi  n-embedded sections. 
 Immunoperoxidase detection systems were Vectastain elite ABC 
reagent and slides were counterstained with Mayer ’ s hematoxylin. 
Human tonsil was used as positive control in each staining batch and 
samples from the same series without primary antibody served as 
negative controls. 
 Histological and immunohistochemical analysis of consecutive 
sections was carried out under a light microscope (Olympus BX43) 
at 10 × to 40 × original magnifi cation and digitized by a video system 
(Olympus, Tokyo, Japan, D70 camera) interfaced to a computer with 
dedicated soft ware (Olympus CellSens Dimension). Between 10 and 
20 digitized microscopic fi elds (20 × and 40 × magnifi cation) of each 
section were analyzed by CellSens Dimension color imaging soft ware 
by two experienced observers (GP and FV) and pixel threshold for 
blue positive area (Masson trichrome stain of fi brosis) and for dark 
brown area (positive immunostained cell area) applied under the 
same microscope light settings. Average values of each section and 
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of each case were thus obtained for blue-stained areas and expressed 
as  percentage of positive/total observed myocardial area. The same 
procedure was applied to dark brown-positive areas of IL-6, CD68 
and MIF immunostained sections as an indirect index of positive cell 
number for each antibody, assuming a similar distribution of each 
marker in all strongly positive cells. A qualitative analysis of MIF and 
IL-6 distribution in CD68 positive cells was also accomplished. 
 Statistics 
 Data are expressed as median and interquartile range (I – III) or fre-
quency (percentage). Normality was analyzed with the Kolmog-
orov-Smirnov test. Diff erences between baseline and post-LVAD 
implantation were assessed by paired Student ’ s t-test or Wilcoxon 
signed-rank test, where appropriate, for continuous variables and 
 χ 2 or Fisher ’ s exact tests for categorical variables. Diff erences with 
INTERMACS profi les were tested by non-parametric Kruskal-Wallis 
test, followed by Bonferroni post-hoc test for pairwise comparisons. 
Spearman ’ s correlation was used to analyze the relationship between 
variables. To assess the infl uence of tested parameters, backward step-
wise multiple linear regression analysis was used. A p-value  < 0.05 was 
considered statistically signifi cant. The SPSS 17 statistical soft ware 
package (SPSS Inc, Chicago, IL, USA) was used for all calculations. 
 Results 
 Patient characteristics and outcome 
 The clinical characteristics of patients are summa-
rized in  Table 1 . Patients were distributed among more 
 Table 1   Clinical characteristics. 
 
 
  INTERMACS group 
  1 (n = 9)   2 (n = 8)   3 (n = 23) 
Age, years   54 (44 – 66)  59 (52 – 62)  51 (48 – 60)
Male gender, n (%)   8 (89)  7 (88)  21 (91)
NYHA class, n (%)
   III   1 (11)  2 (25)  10 (44)
   IV   8 (89)  6 (75)  13 (56)
   Etiology, n (%)
   IDC   5 (56)  4 (50)  15 (65)
   IHD   4 (44)  4 (50)  8 (35)
   Length of stay, days   42 (26 – 102)  45 (31 – 54)  48 (28 – 60)
   ICU stay   21 (12 – 29)  13 (8 – 14)  11 (11 – 17)
   Mortality rate, %   3 (33)  0 (0)  5 (22)
   Treatments, n (%)
   ACEi + ARB   4 (44)  4 (50)  17 (74)
   β -Blocker   2 (22)  5 (63)  22 (96)
   Statins   2 (22)  1 (13)  7 (30)
   Diuretics   7 (78)  5 (63)  23 (100)
   Inotropic   7 (78)  4 (50)  11 (48)
IABP, n (%)   8 (89)  2 (33)  2 (9)
   CI, L/min/m 2   2.09 (1.88 – 2.45)  1.50 (1.30 – 1.70)  1.70 (1.37 – 1.90)
   RAP, mmHg   5 (3 – 14)  6 (4 – 10)  6 (3 – 9)
   PCWP, mmHg   15 (9 – 24)  24 (17 – 33)  26 (22 – 33)
   MAP, mmHg   81 (76 – 84)  90 (90 – 91)  75 (70 – 81)
   LVEF, %   20 (17 – 24)  26 (19 – 28)  23 (20 – 27)
   LVEDV, mL   248 (183 – 321)  190 (170 – 335)  265 (180 – 315)
   LVEDD, mm   68 (58 – 76)  68 (55 – 81)  70 (65 – 76)
eGFR, mL/min/1.73 m 2   80 (55 – 102)  78 (50 – 119)  79 (54 – 89)
Total bilirubin, μmol/L   12.48 (9.06 – 49.59)  14.19 (9.06 – 17.10)  20.35 (10.26 – 30.44)
   tSOFA score, n   6 (5 – 9)  3 (2 – 4)  4 (2 – 5)
   C-reactive protein, nmol/L  78.06 (12.38 – 131.38)  7.14 (3.33 – 19.04)  11.42 (1.90 – 20.94)
   NT-proBNP, ng/L   1058 (447 – 4693)   4185 (2296 – 5690)   4294 (1378 – 6219) 
 Values are presented as mean ( ± SD) or number (percentage). ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor 
blockers; CI, cardiac index; eGFR, estimated glomerular filtration rate; IABP, intra-aortic balloon pump; IDC, idiopathic dilatative cardiomyo-
pathy; IHD, ischemic heart disease; LVEDD, left ventricular end-diastolic diameter; LVEDV, left ventricular end-diastolic volume; LVEF, left 
ventricular ejection fraction; MAP, mean arterial pressure; NT-proBNP, N-terminal pro-hormone brain natriuretic peptide; NYHA, New York 
Heart Association; PCWP, pulmonary capillary wedge pressure; RAP, right atrial pressure; tSOFA, total Sequential Organ Failure Assessment. 
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advanced New York Heart Association (NYHA) classes, 
with idiopathic dilatative cardiomyopathy (IDC) as main 
etiology. 
 Eight patients died during ICU stay [16 (11 – 26) days] 
with MOF as main or secondary cause of death (3 patients 
with INTERMACS profile 1, and 5 with profile 3). At 1 
year the survival rate was 77%. The pre-implant tSOFA 
score was 4 (2 – 6) and significantly worsened to 9 (4 – 10) 
at 1-week post-operative implantation (p < 0.001). After 2 
weeks post-operative implantation, tSOFA score returned 
to pre-implant value [1 (0 – 6), p = 0.063]. 
 Among survivors, length of ICU stay was 13  (8 – 17) 
days, while hospitalization was 49 (41 – 72) days. Ten 
patients underwent HT after LVAD support, while one 
patient was weaned from device due to successful cardiac 
recovery during LVAD-based therapy. 
 Cardiac and circulating IL-6 levels 
 The cardiac IL-6 level was 1.54 (0.42 – 3.50) pg/mg, ranging 
from 0.09 to 39.7 pg/mg, while pre-operative plasma IL-6 
level was 8.15 (3.02 – 25.42) pg/mL, ranging from 0.4 to 
500.5 pg/mL. Cardiac IL-6 levels did not correlate with 
either plasma IL-6 levels (R = 0.296, p = 0.063) and cardiac 
IL-6 mRNA expression [0.015 (0.007 – 0.039), ranging from 
0.002 to 0.094, R = – 0.013, p = 0.954]. 
 Plasma IL-6 concentrations, but not cardiac levels or 
expression, were correlated to pre-operative serum CRP 
concentrations (R = 0.762, p < 0.001) and circulating leuko-
cytes (R = 0.441, p = 0.005). 
 Relationship with INTERMACS profiles 
 Patients were divided into three groups: Group 1 included 
patients with life threatening hypotension and critical 
organ hypoperfusion, despite rapidly escalating inotropic 
support (INTERMACS profile 1, n = 9), Group 2 included 
hemodynamically unstable patients despite optimized 
intensive medical therapy (INTERMACS profile 2, n = 8), 
while Group 3 included patients who were hemodynami-
cally stable although requiring inotropic therapy in the 
majority of the cases (INTERMACS profiles   ≥  3, n = 23). 
 Pre-implant plasma IL-6 levels and serum CRP con-
centrations differed among LVAD candidates of Group 1, 
2 or 3 (p = 0.008 and p = 0.044, respectively). By post-hoc 
comparison test, patients in Group 1 had higher plasma 
IL-6 levels compared to patients in Groups 2 and 3, while 
serum CRP levels were higher only in patients of Group 1 
with respect to those of Group 3 ( Figure 1 ). No differences 
were instead observed in cardiac IL-6 levels with respect 
to INTERMACS profiles (p = 0.090). 
 Relationship with pre-implant tSOFA score 
 Pre-implant tSOFA score was directly related with plasma 
IL-6 (R = 0.607, p < 0.001) and serum CRP (R = 0.586, p < 0.001) 
levels, while no correlation was found with cardiac IL-6, 
either as protein levels and mRNA expression (R = 0.255, 
p = 0.112 and R = 0.049, p = 0.830, respectively). 
 Both plasma IL-6 and CRP variables were tested by 
stepwise multiple linear regression. Only levels of CRP 
were independently associated with pre-implant tSOFA 
score ( β = 0.0264, p = 0.015). 
 Relationships with survival 
 No difference in pre-implant cardiac and plasma levels of 
IL-6 and serum CRP concentrations were found between 
survivors and non-survivors both at 1 year from implanta-
tion or during ICU stay. 
 Relationships with ICU stay, hospitalization 
and post-operative tSOFA score 
 Pre-implant plasma IL-6 levels and CRP concentra-
tions were related with tSOFA score at 2 weeks (R = 0.522, 
p = 0.001, and R = 0.366, p = 0.028, respectively) and with 
ICU stay (R = 0.410, p = 0.009 and R = 0.449, p = 0.004, respec-
tively), but not with hospitalization (R = 0.149, p = 0.358, 
and R = 0.189, p = 0.243, respectively). Instead, cardiac IL-6 
values did not correlate with any of the above clinical 
outcome. 
 The length of ICU stay was not different among LVAD 
candidates with different INTERMACS profiles (p = 0.111). 
 Myocardial histology and 
immunohistochemistry 
 The median value of overall blue-stained collagen area, 
expressed as percentage of total observed myocardial 
area, was 8.2 (5.8 – 14.7)%, and was considered an index 
of total fibrosis; 5.6 (4.7 – 6.8)% was attributed to intersti-
tial fibrosis following exclusion of perivascular and dense 
focal positive areas. 
 The average percentage of dark brown-positive area of 
each antibody tested was comparable among IL-6, CD68 
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 Figure 1   Cardiac (A) and plasma IL-6 (B) and serum CRP (C) levels according to INTERMACS profiles of LVAD recipients. 
 Group 1 (white bars): INTERMACS profile 1; Group 2 (black bars): INTERMACS profile 2; Group 3 (gray bars): INTERMACS profiles   ≥  3. *p < 0.05 
by post-hoc Bonferroni test. 
and MIF, although a much broader variability was found 
for the two latter ones ( Figure 2 A). Qualitative analysis 
revealed that cells positively immunostained by MIF and 
IL-6 antibodies were mostly CD68 positive macrophages 
and, at a lesser extent, endothelial cells of neoformed 
microvessels (Figure 2B). 
 Discussion 
 To our knowledge this is the first study to compare IL-6 
amounts, both at plasma and cardiac level, with peri-
operative risk and outcome of LVAD recipients. The study 
shows that the apical content of IL-6 is not related to 
cytokine concentrations in bloodstream, and with the 
peri-operative risk assessed by INTERMACS profiles. On 
the contrary, plasma IL-6 content correlates with pre-oper-
ative hemodynamic status, post-operative tSOFA score 
and length of ICU stay, thus with the degree of severity of 
clinical course. Also, serum CRP levels predict the degree 
of post-operative severity but it correlates less with the 
pre-operative risk assessed by INTERMACS profile than 
circulating IL-6 concentrations. 
 Cytokines members of the IL-6 superfamily are 
expressed in the myocardium of failing heart, more in 
ESHF patients than in those with recent onset of symp-
toms  [15] , or less severe HF  [9, 16] . Although characterized 
as ESHF patients, LVAD candidates are a heterogeneous 
population with different peri-operative risk grades and 
levels of inflammation  [2, 8] . As previously reported  [8] 
also in this cohort, the circulating levels of IL-6 were dif-
ferently distributed according to INTERMACS value, with 
plasma IL-6 levels higher in patients with profile 1. On the 
contrary, IL-6 cardiac protein and expression were not 
associated with INTERMACS profiles. 
 In LVAD candidates, the peripheral levels of IL-6 
probably derive from other organs in addition to the 
damaged heart. Indeed, plasma IL-6 concentrations of 
our LVAD patients were found related with pre-implant 
tSOFA score. Kidney and liver dysfunctions are present in 
several LVAD recipients, as evidenced by low pre-implant 
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 Figure 2   (A) Percent values of total section area of IL-6, CD68, and MIF positivity. (B): LV-apex immunohistochemical stained for CD68 (a), 
MIF (b), and IL-6 (c) in adjacent sections of LVAD recipient. 
 Original magnification 40 × scale, bar 20  μ m. 
glomerular filtration rate and high bilirubin levels 
found in our patients. Pro-inflammatory cytokines are 
released into the bloodstream from distal sites during 
liver and kidney dysfunctions to orchestrate inflamma-
tory reparative responses against injury  [17] . Otherwise, 
cardiac content and expression of IL-6 may reflect an in 
situ inflammation due to the local infiltration of mac-
rophages; this finding is also supported by myocardial 
immunostaining results that show a co-expression of IL-6 
and MIF, a known factor promoting monocytes and T cells 
recruitment  [18] . However, previous studies reported that 
myocardial IL-6 expression was not different between 
ESHF patients and donors, and not correlated with the 
circulating levels  [15, 16, 19] . 
 Pre-implant plasma IL-6 levels were positively asso-
ciated also to tSOFA score at 2 weeks and to ICU stay, 
showing that this marker may earlier identify patients 
with a complicated clinical course. 
 Likewise to plasma IL-6, pre-implant CRP levels were 
higher in patients with INTERMACS profile 1 and were 
associated to tSOFA score and ICU stay, supporting a rela-
tionship between hemodynamic worsening and inflam-
matory pathways depending on circulating IL-6. CRP is 
produced by hepatocytes predominantly under transcrip-
tional control of this cytokine  [20] . CRP is synthesized in 
the liver as a result of increased IL-6 stimulation, while 
IL-6 is known to play a key role in controlling monocyte 
and endothelial activations  [21] . 
 The use of CRP as prognostic marker of adverse 
outcome in LVAD patients remains still uncertain and 
controversial, although this molecule has been consid-
ered a good indicator of post-operative adverse events in 
surgical patients during stay in the ICU  [22, 23] . However, 
the evaluation of pre-operative CRP levels could help 
clinicians to predict the clinical course of LVAD patients 
using a laboratory tool, routinely present in the biochem-
ical assessment of these subjects. Our results showed that 
pre-operative CRP levels were more associated with indi-
cators of critical course in LVAD patients than IL-6, high-
lighting the better efficiency of CRP in predicting clinical 
outcome. 
 The availability of apical cardiac tissue, excised 
during LVAD implantation, may better integrate clini-
cal and instrumental diagnosis with pathophysiological 
findings obtained from the tissue. However, the most 
interesting use of cardiac biopsies, in the clinical prac-
tice of LVAD therapy, is the identification of accurate 
prognostic cardiac markers, able to provide additional 
information with respect to those in blood. Although a 
previous work reported an increase in myocardium IL-6 
levels  [9] in deteriorating patients who require LVAD 
insertion, in our cohort we did not find any difference. 
Moreover, cardiac levels of IL-6 are less associated with 
the hemodynamic status of LVAD recipients, and do 
not contribute to improved risk prediction in relation 
to clinical course, compared to the circulating levels of 
IL-6 and CRP. 
 Further studies to evaluate the predictive power of the 
combined assessment of the CRP and IL-6 are warranted. 
 Study limitations 
 Four different models of LVAD were used during the study 
period; 29 HeartMate II, six Incor, four De Bakey and one 
HeartWare. Although different pump types do not show 
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differential effects on hemodynamic support  [24] , clinical 
complications associated to different device models may 
differ  [25, 26] . For these reason, we compared incidence of 
the main adverse clinical problems (wound infection, liver 
and renal dysfunction, right ventricular failure, stroke, 
VAD malfunction and aortic insufficiency) in our four 
LVAD groups of patients. No significant differences were 
observed (data not shown). 
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